Upcoming Medical Policies
BlueCross BlueShield of Tennessee

Each medical policy listed below will become effective on the date indicated, and will be included in the Medical Policy Manual for BlueCross BlueShield of Tennessee on that effective date.

Medical policies are developed using an evidence-based evaluation process.  The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and opinions from appropriate network specialists. All Medical Policies are reviewed by a panel of internal and external physicians before being adopted by the company.

Topics due to be included in the Medical Policy Manual on 9/14/2014

Topics due to be included in the Medical Policy Manual on 10/11/2014

Topics due to be included in the Medical Policy Manual on 11/19/2014

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Topics due to be included in the Medical Policy Manual on 9/14/2014:

Donor Lymphocyte Infusion for Hematologic Malignancies

Topics due to be included in the Medical Policy Manual on 10/11/2014:

Ultrafiltration for Decompensated Heart Failure

Topics due to be included in the Medical Policy Manual on 11/19/2014:

Certolizumab Pegol


Last Review Date: 8/19/2014